Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship *

Background:  S‐phase kinase associated protein‐2 (Skp2) ubiquitin ligase p45SKP2 is important in the degradation of p27kip1 (a cyclin dependent kinase inhibitor) and progression through the G1‐S cell‐cycle checkpoint. Low levels of p27 and high levels of Skp2 are related to poor prognosis in some cancers.

[1]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[2]  M. Loda,et al.  Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin‐dependent kinase inhibitor p27Kip1 , 2004, Journal of cutaneous pathology.

[3]  D. Liggitt,et al.  Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development , 2004, Oncogene.

[4]  M. Piris,et al.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.

[5]  K. Nakayama,et al.  Estrogens Down-regulate p27Kip1 in Breast Cancer Cells through Skp2 and through Nuclear Export Mediated by the ERK Pathway* , 2003, Journal of Biological Chemistry.

[6]  M. Loda,et al.  Reciprocal Cdc25A and p27 Expression in B-Cell Non-Hodgkin Lymphomas , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[7]  Edmond Sabo,et al.  Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. , 2003, The Journal of urology.

[8]  M. Pagano,et al.  Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  M. Stanley,et al.  Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression , 2003, International journal of cancer.

[10]  C. Cordon-Cardo,et al.  Oncogenes in melanoma , 2003, Oncogene.

[11]  K. Shigemasa,et al.  Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  G. Linette,et al.  Biomarkers in melanoma: staging, prognosis and detection of early metastases , 2003, Expert review of molecular diagnostics.

[13]  Hong Sun,et al.  Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. , 2003, Cancer research.

[14]  G. Linette,et al.  Biomarkers in melanoma: predisposition, screening and diagnosis , 2003, Expert review of molecular diagnostics.

[15]  R. Lloyd,et al.  Skp2 protein expression in soft tissue sarcomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Martin F. Mihm,et al.  New TNM melanoma staging system: linking biology and natural history to clinical outcomes. , 2003, Seminars in surgical oncology.

[17]  A. Ariza,et al.  Over-Expression of p45SKP2 in Kaposi’s Sarcoma Correlates with Higher Tumor Stage and Extracutaneous Involvement but Is Not Directly Related to p27KIP1 Down-Regulation , 2002, Modern Pathology.

[18]  S. Tripp,et al.  Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. , 2002, Blood.

[19]  J. Gnarra,et al.  Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27Kip1 , 2002, The Prostate.

[20]  S. Ramaswamy,et al.  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. , 2002, The Journal of clinical investigation.

[21]  K. Hemminki,et al.  Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. , 2002, The American journal of pathology.

[22]  S. Hirohashi,et al.  A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. , 2002, The American journal of pathology.

[23]  J. Schneider,et al.  Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. , 2002, International journal of oncology.

[24]  M. Mori,et al.  Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. , 2002, Cancer research.

[25]  M. Pagano,et al.  S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. , 2002, The American journal of pathology.

[26]  L. Naldi,et al.  The epidemiology of skin cancer , 2002, The British journal of dermatology.

[27]  A. Ariza,et al.  Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. , 2002, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[28]  H. Zhang,et al.  Expression of oncogenes, tumour suppressor, mismatch repair and apoptosis-related genes in primary and metastatic melanoma cells. , 2001, International journal of oncology.

[29]  S. Sato,et al.  High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. , 2001, Cancer research.

[30]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Michele Pagano,et al.  Role of the F-Box Protein Skp2 in Adhesion-Dependent Cell Cycle Progression , 2001, The Journal of cell biology.

[32]  D. Germain,et al.  A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT , 2001, Oncogene.

[33]  J. Mestan,et al.  Skp2 is oncogenic and overexpressed in human cancers , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Nakayama,et al.  Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. , 2001, Biochemical and biophysical research communications.

[35]  M. Murphy,et al.  Can we reliably use markers of cell cycle regulation (e.g. Ki‐67, p21, p27, p53) to differentiate between benign and malignant skin tumors? , 2001, Journal of cutaneous pathology.

[36]  J. Zheng,et al.  The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. , 2001, Biochemical and biophysical research communications.

[37]  M. Pagano,et al.  Role of the F-box protein Skp2 in lymphomagenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Bartek,et al.  Aberrant p27Kip1 promoter methylation in malignant melanoma , 2000, Oncogene.

[39]  M. Loda,et al.  Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  K. Weinberg,et al.  Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Hemminki,et al.  Analysis of G1/S checkpoint regulators in metastatic melanoma , 2000, Genes, chromosomes & cancer.

[42]  M. Kitagawa,et al.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication , 2000, The EMBO journal.

[43]  J. Carlson,et al.  Topoisomerase II‐alpha expression in melanocytic nevi and malignant melanoma , 2000, Journal of cutaneous pathology.

[44]  I. Weinstein,et al.  Multiple functions of p27Kip1 and its alterations in tumor cells: a review , 2000, Journal of cellular physiology.

[45]  M. Pagano,et al.  Regulation of the Cdk inhibitor p27 and its deregulation in cancer , 2000, Journal of cellular physiology.

[46]  P. Gibbs,et al.  Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. , 2000, Journal of the American Academy of Dermatology.

[47]  Lee,et al.  Reduced expression of the cell‐cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma , 2000, Histopathology.

[48]  E. Medrano,et al.  High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. , 1999, The Journal of investigative dermatology.

[49]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[50]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[51]  Wilhelm Krek,et al.  p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells , 1999, Nature Cell Biology.

[52]  Hong Sun,et al.  p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 , 1999, Current Biology.

[53]  C. Rescan,et al.  Skp2 induction and phosphorylation is associated with the late G1 phase of proliferating rat hepatocytes , 1999, FEBS letters.

[54]  M. Scheffner,et al.  Interaction between ubiquitin–protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation , 1999, Nature Cell Biology.

[55]  S. Cowper,et al.  Expression of p-27 (kip1) in nevi and melanomas. , 1999, The American Journal of dermatopathology.

[56]  F. Shepherd,et al.  Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. , 1999, Cancer research.

[57]  M. Loda,et al.  Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. , 1998, The American journal of pathology.

[58]  Robert S. Kerbel,et al.  E-Cadherin–dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1 , 1998, The Journal of cell biology.

[59]  J. Nesland,et al.  Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.

[60]  James M. Roberts,et al.  The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury , 1998, Nature Medicine.

[61]  M. Loda,et al.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.

[62]  M. Loda,et al.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.

[63]  Esposito,et al.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. , 1997, Cancer research.

[64]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[65]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[66]  G. Wang,et al.  Induction of the , 1996 .

[67]  D. Demetrick,et al.  Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). , 1996, Cytogenetics and cell genetics.

[68]  R. Kobayashi,et al.  pl9 skp1 and p45 skp2 are essential elements of the cyclin A-CDK2 S phase kinase , 1995, Cell.

[69]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[70]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[71]  James M. Roberts,et al.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. , 1995, Cancer research.

[72]  D. Elder,et al.  Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. , 1991, Human pathology.